Prime Medicine doses first patient with prime editing inside the body for Wilson disease

Nature reported on October 22, 2026 that Prime Medicine had dosed the first patient with PM577a, an in vivo prime editing therapy designed to correct the H1069Q mutation in ATP7B inside liver cells. The Cambridge, Massachusetts company, which trades on Nasdaq as PRME, said the treatment is the first known use of prime editing directly inside a human body. The milestone is part of a clinical trial for Wilson disease, a rare inherited disorder of copper metabolism. It marks a shift from editing cells in a laboratory to editing them inside the patient.

Wilson disease affects about 1 in 30,000 people globally, according to ChosunBiz. Mutations in ATP7B impair a protein that moves excess copper out of liver cells and into bile. When copper accumulates, it can damage the liver and nervous system and cause neurological problems. Current care relies on copper-binding drugs or zinc preparations, often for life, and severe liver failure may require a transplant. These options can manage copper but do not correct the underlying genetic defect.

Prime editing is a CRISPR-based technique released in Nature in 2019 by the Broad Institute, which Harvard University and MIT jointly founded. Standard CRISPR-Cas9 cuts both DNA strands and relies on cellular repair, which can produce unwanted insertions or deletions. Prime editing cuts one strand and uses an enzyme plus a guide RNA to write a new sequence. It can substitute among A, T, G and C and insert or delete short sequences. Base editing can rewrite single DNA letters but cannot make the corrections needed for the most common ATP7B mutations, Nature reported.

The difference between ex vivo and in vivo editing is central. Casgevy, the only gene-editing therapy approved by the FDA, uses CRISPR-Cas9 and edits blood stem cells outside the body. Prime Medicine previously treated two people with a rare immune disorder by editing blood stem cells outside the body. For Wilson disease, PM577a is given as a single intravenous infusion. Lipid nanoparticles, similar to the delivery technology used in COVID-19 mRNA vaccines, carry the editing tools to liver cells. In-body editing avoids collecting, modifying and reinjecting a patient's cells, a process that often requires harsh chemotherapy.

Key Facts

GlobeNewswire reported on October 5, 2026 that Prime Medicine had dosed the first patient in a global Phase 1/2 trial of PM577a. The open-label, first-in-human study is listed as NCT07748403. It plans to enroll 42 participants aged 12 and older across 4 sites in 2 countries, including Texas Liver Institute and NZCR Grafton. The study uses ascending doses in adults and adolescents with at least one p.H1069Q allele in ATP7B. It begins with adults clinically stable on standard of care. Primary follow-up lasts 48 weeks, and a long-term study is expected to run about 15 years. Initial data are expected in 2027, with primary completion projected for late 2028.

ChosunBiz reported on October 23, 2026 that PM577a targets H1069Q, a mutation common in North America and Europe. Prime Medicine says the mutation accounts for about 30% to 50% of ATP7B mutations causing Wilson disease in the US and Europe. A follow-on candidate for R778L, common in East Asia, remains preclinical. PM577 is a family of lipid nanoparticle-formulated prime editing products designed to correct pathogenic ATP7B mutations in hepatocytes after a single intravenous infusion. The company has positioned PM577a as a potential one-time treatment that acts before irreversible liver and neurological damage occurs.

The trial will track more than simple safety. Efficacy measures may include copper efflux by 64Cu PET, serum ceruloplasmin, non-ceruloplasmin-bound copper and 24-hour urinary copper excretion. The protocol will also evaluate whether patients can discontinue baseline standard of care therapies. That endpoint matters because current chelators and zinc salts are not curative, require lifelong daily treatment and carry tolerability and adherence challenges. Liver transplantation is the only curative option, but it is constrained by organ availability and procedural risk. The FDA granted Rare Pediatric Disease designation to PM577 for Wilson disease, according to the company announcement.

Prime Medicine CEO Allan Reine called dosing the first patient a meaningful step toward a transformative, one-time treatment. Chief Medical Officer Mohammed Asmal said PM577a is designed to correct H1069Q at its genetic root through a single administration. The regulatory context remains early. The FDA has approved only one gene-editing therapy, Casgevy, and no in vivo gene-editing therapy has been approved. The FDA is expected to decide early next year on an in vivo CRISPR-Cas9 therapy for hereditary angioedema. Rhonda Rowland, president of the Wilson Disease Association in Atlanta, Georgia, said she never dreamed she would see this applied to her rare disease.

Analysis

What this really means is that prime editing has crossed from laboratory proof of concept into a human test of direct DNA correction, but the milestone is about feasibility and safety, not proven benefit. The first patient has been dosed, not cured. The trial is an open-label, first-in-human study of ascending doses, and the company expects initial results next year. Those results will need to show that the editing tools reach liver cells, correct the intended sequence, and improve copper handling enough to matter clinically. The rationale is strong, but the clinical bar is high because Wilson disease can be managed imperfectly with existing drugs.

The safety questions are direct for an in-body therapy. The Independent reported on October 23, 2026 that experts caution doctors cannot verify edits are accurate before cells begin replicating. Krishanu Saha, a biomedical engineer at the University of Wisconsin-Madison, said precise delivery to target organs remains the core challenge and that it depends on what types of risks you are willing to accept. Off-target edits could persist long term. Lipid nanoparticles are established from mRNA vaccines, but they must reach the intended organ precisely and minimize unintended editing. The trial starts with adults stable on standard care, which reflects that caution.

The bigger picture here is that in-body editing could change the economics of genetic medicine if it works. Joseph Thome, a biotechnology analyst at TD Cowen, told The Independent that these genetic-medicine companies are not cheap to fund, and that direct treatments could cut production costs and widen access. Ex vivo therapies require collecting a patient's cells, modifying them in a specialized facility and reinjecting them, often after harsh chemotherapy. An off-the-shelf intravenous infusion could be faster and cheaper to manufacture and administer. That does not guarantee a low price, but it changes the cost structure.

Prime Medicine's choice of H1069Q is also a calculated bet. The mutation is the most prevalent Wilson disease-causing allele in North America and Europe, and the company says it accounts for roughly 30% to 50% of ATP7B mutations in those regions. A single product can therefore address a meaningful share of patients in major markets. The follow-on R778L program, aimed at East Asian populations, remains preclinical. If PM577a works, the platform could be adapted to other ATP7B mutations, but each change would need its own validation. The trial is a test of the platform as much as of one drug.

Why It Matters

For patients with Wilson disease, the appeal is a possible one-time treatment. Current chelators and zinc salts are not curative, require lifelong daily treatment and carry tolerability and adherence challenges. Liver transplantation can cure the metabolic defect but depends on organ availability and carries procedural risk. PM577a is designed to correct the H1069Q mutation in liver cells so they can remove excess copper. If the trial shows durable copper control and allows patients to stop standard therapy, the impact on daily life would be substantial. Rowland's comment captures the stakes for a rare disease community.

For the gene-editing field, the first in vivo prime editing trial is a test of delivery and regulation. Prime editing is more precise than standard CRISPR-Cas9, but precision inside the body depends on reaching the right cells and avoiding edits elsewhere. The FDA has not approved any in vivo gene-editing therapy. Its expected decision early next year on an in vivo CRISPR-Cas9 therapy for hereditary angioedema will set an important precedent. A positive result would not settle those questions, but it would strengthen the case that in-body editing can be practical.

For drug developers and investors, the trial is a signal about manufacturing and access. In-body editing removes the need to collect and process cells for each patient, cutting time and manufacturing cost. That could widen access if payers and health systems accept the value of a one-time treatment. It could also attract more investment into rare disease gene editing. The risk is that safety signals or weak efficacy could slow the category. The early data in 2027 will be watched well beyond the Wilson disease community.

Next Up

Prime Medicine expects initial clinical data in 2027. The Phase 1/2 trial continues to enroll adults and adolescents aged 12 and older at sites including Texas Liver Institute and NZCR Grafton. The 48 week primary follow-up and the roughly 15 year long-term study will track safety, dosing, copper excretion and whether patients can discontinue standard care. Primary completion is projected for late 2028. The company is also developing a preclinical follow-on candidate for R778L, the most common mutant allele in East Asian populations.

The regulatory calendar adds another near-term test. The FDA is expected to decide early next year on an in vivo CRISPR-Cas9 therapy for hereditary angioedema. That decision, along with Prime Medicine's first data, will shape how quickly in-body gene editing moves from a first-in-human milestone to a broader therapeutic option. For now, the Wilson disease trial is the first known use of prime editing directly inside a human body.